Spectral Medical Q3 revenue up 34%

Spectral Medical

07/11/2025 12:38

Overview

Spectral Q3 2025 revenue rises 34% yr/yr, driven by higher product revenue

Company targets Q1 2026 for PMA submission following positive Tigris trial results

Tigris trial met primary endpoint with 95.3% probability of benefit for 28-day mortality

Outlook

Spectral targets PMA submission for PMX in Q1 2026

Spectral focuses on completing regulatory submission package after positive Tigris results

Result Drivers

Operating expenses for the three-months ended September 30, 2025, were C$30,800,000 compared to C$ 10,409,000 for the same period in the preceding year,

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q3 Revenue
C$675,000


Analyst Coverage

The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 2 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

The average consensus recommendation for the pharmaceuticals peer group is "buy."

Wall Street's median 12-month price target for Spectral Medical Inc is C$3.10, about 53.5% above its November 6 closing price of C$1.44

Press Release: ID:nGNX82jqL

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)